DDInter1309 DDInter1435
A histamine H2 receptor antagonist with low toxicity that inhibits gastric acid secretion. The drug is used for the treatment of duodenal ulcers.
Pexidartinib is a selective tyrosine kinase inhibitor that works by inhibiting the colony-stimulating factor (CSF1)/CSF1 receptor pathway. Pexidartinib was originally developed by Daiichi Sankyo, Inc. and it was approved by the FDA in August 2019 as the first systemic therapy for adult patients with symptomatic tenosynovial giant cell tumor. Tenosynovial giant cell tumor is a rare form of non-malignant tumor that causes the synovium and tendon sheaths to thicken and overgrow, leading to damage in surrounding joint tissue.[A182240,L7901] Debilitating symptoms often follow with tenosynovial giant cell tumors, along with a risk of significant functional limitations and a reduced quality of life in patients. While surgical resection is a current standard of care for tenosynovial giant cell tumor, there are tumor types where surgeries are deemed clinically ineffective with a high risk of lifetime recurrence. Pexidartinib works by blocking the immune responses that are activated in tenosynovial giant cell tumors. In clinical trials, pexidartinib was shown to promote improvements in patient symptoms and functional outcomes in TGCT. Pexidartinib is available in oral formulations and it is commonly marketed as Turalio.
Nizatidine {u} (Compound) resembles {v} (Compound) Ranitidine
Nizatidine {u} (Compound) binds {v} (Gene) HRH2
Nizatidine {u} (Compound) upregulates {v} (Gene) RAB27A
Nizatidine {u} (Compound) is included by {v} (Pharmacologic Class) Histamine H2 Receptor Antagonists
Nizatidine {u} (Compound) downregulates {v} (Gene) SLC35B1
Nizatidine {u} (Compound) causes {v} (Side Effect) Sinusitis
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Flurbiprofen
Nizatidine {u} may cause a minor interaction that can limit clinical effects when taken with {v} Ketorolac
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Bosutinib
Nizatidine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Gefitinib
Nizatidine (Compound) resembles Ranitidine (Compound)
Nizatidine (Compound) binds HRH2 (Gene)
Nizatidine (Compound) upregulates RAB27A (Gene)
Nizatidine (Compound) is included by Histamine H2 Receptor Antagonists (Pharmacologic Class)
Nizatidine (Compound) downregulates SLC35B1 (Gene)
Nizatidine (Compound) causes Sinusitis (Side Effect)
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Flurbiprofen
Nizatidine may cause a minor interaction that can limit clinical effects when taken with Ketorolac
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Bosutinib
Nizatidine may cause a moderate interaction that could exacerbate diseases when taken with Gefitinib